The First 3 Months

The first 3 months of the contract were a blur of training courses at both the mine and the plant. We were training some 30 smdoits a day on the inspecting and auditing class, and enthusiasm for the system, and especially to clean up the woik areas, was escalating. 

The union was on board, managanent was on board, and there was a political race between the plant and the mine to be first to reach the five-star safety standard. 

---

The point to consider with repacked GPC/SEC columns is the warranty. Because the columns are fragile, warranties are very important. American Polymer Standards offers a 90-day unconditional warranty on every repacked column. This type of warranty is especially useful for beginners, who would typically make mistakes within the first 3 months of GPC/SEC work. 

The patient is reexamined shortly after the first menses after insertion or within the first 3 months and at any time the patient exhibits symptoms. 

At present, many clients ate teferred by the courts and thus are required to complete treatment. Anothet tecent change has been that entrants appear to be more depressed and less intelligent and to have more behavioral problems than in the past (DeLeon 1985). Even in the past, when chents had to demonstrate high levels of motivation to gain admission, dtopout tates wete high (DeLeon 1985). About 50% of patients drop out within the first 3 months, and only about 15% of entrants complete a year of treatment. 

After discharge, all infants were followed by a team composed of a pediatrician with subspecialty training in Child Development, a public health nurse, and a social worker. In order to maintain contact with the foster families and relatives who had responsibility for the care of the infant, team members made regular home visits and had frequent telephone contact with the infants caretakers. During the first 3 months of placement, infants were seen (an average of twice per month) for follow-up visits at home or in the UCLA Child Development Clinic. Phone conferences with caretakers were held on a biweekly basis. During the foil owing 3 months, clinic and home visits were tapered to once per month and phone contacts were made biweekly. 

Use of zileuton is uncommon due to the need for dosing four times a day, potential drug interactions, and the potential for hepatotoxicity with the resulting need for frequent monitoring of liver enzymes. In patients started on zileuton, serum alanine aminotransferase concentrations should be monitored before treatment begins, monthly for the first 3 months, every 2 to 3 months for the remainder of the first year, and then periodically thereafter for as long as the patient continues to receive the medication. Zileuton also inhibits the cytochrome P-450 (CYP) mixed function enzyme system and has been shown to decrease the clearance of theophylline, R-warfarin and propranolol.34... 

Oxcarbazepine Hyponatremia (serum sodium concentrations less than 125 mEq/L) has been reported and occurs more frequently during the first 3 months of therapy serum sodium concentrations should be monitored in patients receiving drugs that lower serum sodium concentrations (e.g., diuretics or drugs that cause inappropriate antidiuretic hormone secretion) or in patients with symptoms of hyponatremia (e.g., confusion, headache, lethargy, and malaise). Hypersensitivity reactions have occurred in approximately 25-30% of patients with a history of carbamazepine hypersensitivity and requires immediate discontinuation. 

Monitor clinical symptoms associated with hyperprolactinemia every month for the first 3 months to assess therapeutic efficacy and assist with dose titration. 

It is imperative that the initiation of one or more disease-modifying antirheumatic drugs occurs in all patients within the first 3 months of diagnosis to reduce joint erosion. 

Evaluate patients taking allopurinol for development of rash, nausea, or new fever. These symptoms usually appear within the first 3 months of therapy but can occur anytime. 

The success of antiretroviral therapy is measured by the degree to which the therapy (1) restores and preserves immunologic function, (2) maximally and durably suppresses HIV RNA, (3) improves quality of life, and (4) reduces HIV-related morbidity and mortality. The major outcome parameters are CD4+ lymphocyte absolute count and percentage, and plasma HIV RNA. Adequate immunologic response in antiretroviral-naive patients consists of an increase in CD4+ cell count that averages 100 to 150 cells/mm3 per year (with a faster response in the first 3 months), and a 1 log decrease in HIV RNA by 2 to 8 weeks after starting... 

The patient should be assessed in 2 to 4 weeks following the implementation of therapy to determine effectiveness of and intolerance to treatment. Monthly visits are encouraged during the first 3 months. More frequent follow-up maybe necessary in the presence of other medical conditions. Less frequent followup occurs after 6 months of effective weight-loss therapy. 

It will be assumed that the plant runs at full capacity after January 1975. The profit made in the first 3 months of operation will be assumed to cover all startup expenses. 

A disease-modifying antirheumatic drug (DMARD) should be started within the first 3 months of symptom onset (Fig. 4-1). DMARDs should be used in all patients except those with limited disease. Early use of DMARDs results in a more favorable outcome and can reduce mortality. 

Ticlopidine is associated with neutropenia that requires frequent monitoring of the complete blood cell count during the first 3 months of use. For this reason, clopidogrel is the preferred thienopyridine for ACS and PCI patients. 

Major adverse effects include agranulocytosis (with fever, malaise, gingivitis, oropharyngeal infection, and a granulocyte count less than 250/mm3), aplastic anemia, a lupus-like syndrome, polymyositis, GI intolerance, hepatotoxicity, and hypoprothrombinemia. If it occurs, agranulocytosis almost always develops in the first 3 months of therapy routine monitor-... 

When a patient is stabilized on medication, less frequent monitoring is possible during the continuation phase (e.g, every month for the first 3 months, then every 2-3 months)... 

Naltrexone is hepatotoxic and contraindicated in patients with hepatitis or liver failure. LFTs should be monitored monthly for the first 3 months, then every 3 months. Side effects include nausea, headache, dizziness, nervousness, insomnia, and somnolence. 

Use of zileuton is limited due to the potential for elevated hepatic enzymes (especially in the first 3 months of therapy), and inhibition of the metabolism of some drugs metabolized by CYP3A4 (e.g., theophylline, warfarin). Serum alanine aminotransferase should be monitored before treatment and then periodically thereafter. 

A commercial-scale Improved B-1, with a capacity of 10 000 metric tonnes per year (caustic base), came into operation successfully at the AGC Kashima factory in July 1999. Since then, the plant has demonstrated a long-run operation to prove its stable performance and durability under high current density. For the first 3 months, the electrolyser was operated at 5kA m-2. Then the current density was increased step by step up to 7kA m-2. An Fx-8964 membrane, which had just been developed as one of the optional membranes for high current density, was installed. The operation was observed to be stable for each current density. As is shown in Fig. 19.7, the power consumption at present is approximately 2300 (d.c.) kWh tonne-1 at 7 kA m-2. 

Flosequinan has a positive inotropic effect and shows a tendency to increase the heart rate, atrioventricular conduction in patients with atrial fibrillation and neurohormonal activation. Although the precise mechanisms involved have remained unclear up to now [29], this drug has been used to treat congestive heart failure (CHF). The FDA approved flosequinan (Manoplax) in 1993. However, the drug was withdrawn a year later because the PROFILE (prospective randomized flosequinan longevity evaluation) study indicated that flosequinan had adverse effects on survival, and that beneficial effects on the symptoms of heart failure did not last beyond the first 3 months of therapy, after which patients on the dmg had a higher rate of hospitalization than patients taking a placebo [14]. 

The use of peat as Utter was compared with sawdust and straw on 15 dairy farms during the indoor feeding period of 1983-84. For the first 3 months 5 farms used straw as litter, 5 used sawdust and 5 peat. At the end of this period all the farms changed over to peat litter. All the cowsheds had tying-stalls, from which the manure was removed in solid form. 

Hematologic Rosiglitazone and pioglitazone may cause decreases in hemoglobin and hematocrit. These changes primarily occurred within the first 4 to 12 weeks for pioglitazone and the first 3 months of rosiglitazone therapy. 

Biood dyscrasias Agranulocytosis, bone marrow depression, neutropenia, hypoplastic anemia and thrombocytopenia in patients receiving procainamide have been reported at a rate of approximately 0.5%. Fatalities have occurred (with approximately 20% to 25% mortality in reported cases of agranulocytosis). Perform complete blood counts including white cell, differential, and platelet counts at weekly intervals for the first 3 months of therapy, and periodically thereafter. Perform complete blood counts promptly if the patient develops any signs of infection (eg. 

Hematologic disturbances Agranulocytosis with fever and sepsis has occurred. Unexplained fever or decrease in white cell count, particularly during the first 3 months of therapy, warrants consideration of possible agranulocytosis/granulocytopenia. 

---